Vancouver, British Columbia / TheNewswire / (February 27th, 2018)–BioMark Diagnostics Inc. (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) announces the award of a grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) to partner with Donald Miller, Ph.D., Professor, Department of  Pharmacology and Therapeutics  at the University of Manitoba, to fabricate new nanomaterial and focus on evaluation of these new nanomaterial for knocking down SSAT1 expression in various cells .The up regulation of  SSAT enzyme  has been clinically demonstrated by BioMark and others to be highly elevated in  lung, breast, prostate and brain cancers.  

  

President and CEO, Rashid Ahmed explains, “We are delighted to be working with Dr. Miller and his team at the University of Manitoba to help BioMark assess the potential of designing new nanomaterials that can be used to target the metabolic pathway associated in the up-regulation of SSAT for various cancers.   Dr. Miller has domain expertise and over 20 years of experience in fabricating, evaluating and developing polymer and metal oxide based nanoparticle compounds and delivery systems for various applications including the brain. He will direct the project and supervise the design of these novel nanomaterial candidates which provide more options to deliver a knock down SSAT compound enabling a potential better treatment associated with various cancers.”

 

Rashid says, “BioMark is grateful to the Canadian government for awarding it yet another grant that supports work to advance this important technology toward commercialization.”

 

About National Sciences and Engineering Research Council of Canada (NSERC) Engage Grants

 

Engage Grants are intended to foster the development of new research partnerships between academic researchers and companies, and supports research and development projects aimed at addressing a company-specific problem.  This initial Engage grant extends over a six month period, with potential opportunities for follow-up funding.  

 

About BioMark Diagnostics Inc.

 

BioMark Diagnostics is developing proprietary, non-invasive, and accurate cancer diagnostic solutions, which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

 

Further information about BioMark Diagnostics is available under its profile on the SEDAR website www.sedar.com and on the CSE website www.thecse.ca.

 

Company Contact                                                

Rashid Ahmed Bux                                                

President & CEO                                               

BioMark Diagnostics Inc.                                       

604-370-0779                                                        

info@biomarkdiagnostics.com  

 

Forward-Looking Information

 

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark.  Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

 

The CSE has not reviewed, approved or disapproved the content of this press release.